239 related articles for article (PubMed ID: 3283185)
21. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
Jacobs SS; Fox E; Dennie C; Morgan LB; McCully CL; Balis FM
Clin Cancer Res; 2005 Feb; 11(4):1669-74. PubMed ID: 15746072
[TBL] [Abstract][Full Text] [Related]
22. Oxaliplatin: pharmacokinetics and chronopharmacological aspects.
Lévi F; Metzger G; Massari C; Milano G
Clin Pharmacokinet; 2000 Jan; 38(1):1-21. PubMed ID: 10668856
[TBL] [Abstract][Full Text] [Related]
23. Atypical pharmacokinetics and excretion of new platinum analogues in rodents.
Webster LK; Ellis AG; Apicella C; Deacon GB
Cancer Chemother Pharmacol; 2002 Jan; 49(1):87-92. PubMed ID: 11855757
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic evaluation of zeniplatin in humans.
DeMarco LC; Budman DR; Lathia C; Amorusi P; Birkhofer M; Lichtman S; Weiselberg L; Vinciguerra V; Lovecchio J; Gal D
Cancer Chemother Pharmacol; 1995; 36(1):35-40. PubMed ID: 7720173
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.
Harland SJ; Newell DR; Siddik ZH; Chadwick R; Calvert AH; Harrap KR
Cancer Res; 1984 Apr; 44(4):1693-7. PubMed ID: 6367971
[TBL] [Abstract][Full Text] [Related]
26. Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients.
Kangarloo SB; Gangopadhyay SB; Syme RM; Wolff JE; Glück S
Med Oncol; 2004; 21(1):9-20. PubMed ID: 15034209
[TBL] [Abstract][Full Text] [Related]
27. Comparative distribution and excretion of carboplatin and cisplatin in mice.
Siddik ZH; Jones M; Boxall FE; Harrap KR
Cancer Chemother Pharmacol; 1988; 21(1):19-24. PubMed ID: 3277732
[TBL] [Abstract][Full Text] [Related]
28. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
29. A comparative binding of platinum anti-tumour compounds to plasma proteins in the rat (in vivo) and mouse (in vitro).
Perera A; Jackson H; Sharma HL; McAuliffe CA; Fox BW
Chem Biol Interact; 1992 Dec; 85(2-3):199-213. PubMed ID: 1493609
[TBL] [Abstract][Full Text] [Related]
30. Single-dose pharmacokinetics of a novel oral platinum cytostatic drug ([OC-6-43]-bis[acetato][1-adamantylamine]amminedichloroplatinum [IV]) in pigs.
Cermanova J; Chladek J; Soval P; Kroutil A; Semerad M; Berankova Z; Siroky P; Surova I
Methods Find Exp Clin Pharmacol; 2004 Nov; 26(9):679-85. PubMed ID: 15632953
[TBL] [Abstract][Full Text] [Related]
31. Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812).
Tutsch KD; Arzoomanian RZ; Alberti D; Tombes MB; Feierabend C; Robins HI; Spriggs DR; Wilding G
Invest New Drugs; 1999; 17(1):63-72. PubMed ID: 10555124
[TBL] [Abstract][Full Text] [Related]
32. Platinum concentrations in uterus and serum after internal iliac arterial infusion of platinum compounds in rabbits.
Kigawa J; Minagawa Y; Itamochi H; Kanamori Y; Ishihara H; Terakawa N
Obstet Gynecol; 1995 Aug; 86(2):265-8. PubMed ID: 7617358
[TBL] [Abstract][Full Text] [Related]
33. Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin.
Newell DR; Siddik ZH; Gumbrell LA; Boxall FE; Gore ME; Smith IE; Calvert AH
Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1399-405. PubMed ID: 3315699
[TBL] [Abstract][Full Text] [Related]
34. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate.
Brouwers EE; Tibben MM; Rosing H; Hillebrand MJ; Joerger M; Schellens JH; Beijnen JH
J Mass Spectrom; 2006 Sep; 41(9):1186-94. PubMed ID: 16929560
[TBL] [Abstract][Full Text] [Related]
35. Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo.
van der Vijgh WJ; Korst AE
Eur J Cancer; 1996; 32A Suppl 4():S26-30. PubMed ID: 8976819
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin.
Figg WD; Christian MC; Lush R; Link CJ; Davis P; Kohn E; Sarosy G; Rothenberg ML; Weiss RB; Ryan N; Jacobs J; Reed E
Biopharm Drug Dispos; 1997 May; 18(4):347-59. PubMed ID: 9158882
[TBL] [Abstract][Full Text] [Related]
37. Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time.
Boughattas NA; Hecquet B; Fournier C; Bruguerolle B; Trabelsi H; Bouzouita K; Omrane B; Lévi F
Biopharm Drug Dispos; 1994 Dec; 15(9):761-73. PubMed ID: 7888604
[TBL] [Abstract][Full Text] [Related]
38. Cisplatin pharmacokinetics in children with cancer.
Peng B; English MW; Boddy AV; Price L; Wyllie R; Pearson AD; Tilby MJ; Newell DR
Eur J Cancer; 1997 Oct; 33(11):1823-8. PubMed ID: 9470840
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV (CHIP) in patients with advanced cancer.
Pendyala L; Greco W; Cowens JW; Madajewicz S; Creaven PJ
Cancer Chemother Pharmacol; 1983; 11(1):23-8. PubMed ID: 6883623
[TBL] [Abstract][Full Text] [Related]
40. Comparison of carboplatin pharmacokinetics between an anephric child and two children with normal renal function.
Koren G; Weitzman S; Klein J; Moselhy G
Med Pediatr Oncol; 1993; 21(5):368-72. PubMed ID: 8388075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
